October 21, 2015 10:53am

After a sector trip, the blow-back is stinging, KITE is DOWN -$0.34 or -0.52% to $66.73. Everyone <sector participants> will “feel” the ATHX “parting of ways”


 

Directed against MAGE A3, A3/A6 antigens to treat tumors expressing MAGE, including lung, pancreatic, gastric and breast cancers

 

National Cancer Institute (NCI) is currently conducting two P1-2a trials of TCR-based product candidates targeting MAGE antigens under Cooperative R&D Agreement between KITE and NCI

 

The Bottom Line: KITE to make upfront payment to NIH, certain clinical, regulatory, sales milestone payments, as well as royalties on net sales of products